HC Wainwright Has Positive Forecast for Valneva Q3 Earnings

Valneva SE Sponsored ADR (NASDAQ:VALN) – Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Valneva in a research note issued on Thursday, March 19th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.19). The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s FY2026 earnings at ($0.81) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.05 EPS.

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Stock Down 1.6%

VALN stock opened at $10.32 on Monday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85. The stock has a market capitalization of $888.66 million, a P/E ratio of -6.53 and a beta of 1.79. The business has a 50-day moving average of $10.29 and a 200-day moving average of $9.69. Valneva has a fifty-two week low of $5.43 and a fifty-two week high of $12.25.

Institutional Investors Weigh In On Valneva

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VALN. Frazier Life Sciences Management L.P. bought a new stake in Valneva during the 2nd quarter worth about $8,240,000. Marex Group plc bought a new position in shares of Valneva in the 2nd quarter valued at about $64,000. JPMorgan Chase & Co. acquired a new stake in shares of Valneva in the third quarter valued at about $124,000. VSM Wealth Advisory LLC raised its holdings in Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Valneva during the fourth quarter worth about $44,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.